J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Ascentage hopes to become a new force in BTK.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
But there are no efficacy data, and the mechanism has a mountain to climb.
